Shares of Vanda Pharmaceuticals climbed 39% to $7.90 in premarket trading Monday, reflecting intense investor optimism following the regulatory win. The stock had already demonstrated significant momentum prior to the announcement, rising more than 32% over the past year. Analysts view this approval as a pivotal expansion of the company’s footprint in the neuropsychiatric space.

The FDA's decision authorizes Bysanti for the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as the management of schizophrenia in adult patients. Vanda stated that the approval addresses a critical need for alternative therapies in the highly competitive mental health market.

Commercial Strategy and Patent Runway

Vanda expects to make Bysanti commercially available by the third quarter of 2024. To safeguard its revenue streams and prevent immediate generic competition, the company is relying on a combination of regulatory data exclusivity and a robust portfolio of issued U.S. patents.

According to the company, its intellectual property framework provides a long-term runway for the drug's adoption:

• Regulatory data exclusivity granted upon FDA approval
• Multiple issued U.S. patents covering the formulation
• A final patent expiration date extending to 2044